Standard BioTools Inc. (LAB) vs Rocket Pharmaceuticals, Inc. (RCKT)
A side-by-side comparison of Standard BioTools Inc. and Rocket Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LAB
Standard BioTools Inc.
$0.72HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RCKT
Rocket Pharmaceuticals, Inc.
$2.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LAB vs RCKT
growth of $100 · dividends reinvested · last 10yLAB -90.2% (-20.7%/yr)RCKT -92.8% (-23.1%/yr)LAB compounded faster over this window
LAB RCKT
LAB vs RCKT: by the numbers
- •LAB is the larger company ($283M vs $271M market cap).
- •Both run net losses; RCKT's is the smaller (0.00% vs -103.29% net margin).
Metrics side by side
Valuation
| Metric | LAB | RCKT |
|---|---|---|
| P/S ratio | 3.34 | N/A |
| P/B ratio | 0.52 | 0.73 |
Profitability
| Metric | LAB | RCKT |
|---|---|---|
| Gross margin | 49.14% | 0.00% |
| Operating margin | -109.34% | 0.00% |
| Net margin | -103.29% | 0.00% |
| ROE | -16.18% | -4.68% |
| ROIC | -14.06% | -48.92% |
Growth (annualized)
| Metric | LAB | RCKT |
|---|---|---|
| Revenue CAGR (5Y) | -10.62% | N/A |
| Total return CAGR (5Y) | -32.98% | -38.33% |
Frequently asked
- How have LAB and RCKT total returns compared?
- Over the past 10 years, LAB delivered -20.93% and RCKT delivered -23.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.